Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:
Journal of the ASEAN Federation of Endocrine Societies · 13.11.2025 · 40 (2) · 69-77
DOI: 10.15605/jafes.040.02.22 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the ASEAN Federation of Endocrine Societies, online erschienen am 13.11.2025. Verfasst von Peachaphol Chongvoranond und 7 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes, Thyroid, and Endocrine Center, Vimut-Theptarin Hospital, Bangkok, Thailand. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Albuminuria. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Despite the beneficial effects of SGLT2i in reducing kidney disease progression and mortality in people with diabetic kidney disease (DKD), the use of SGLT2i in this population remains low.
Objective
To explore the prescription rates of SGLT2i in type 2 diabetes (T2D) patients with albuminuric DKD and to assessclinician-perceived barriers to prescribing SGLT2i.Methodology. A retrospective study of all medical records of T2D patients with albuminuric DKD and eGFR ≥20 ml/min/1.73 m2 in 2023 who had been treated by 13 diabetologists was conducted at Vimut-Theptarin Hospital, a private tertiary diabetes center in Bangkok. In cases of no documentation of non-prescribed SGLT2i, treating physicians were contacted to explore the reasons.
Result
A total of 282 medical records were reviewed (mean age 65.9 ± 10.0 years, A1C 7.5 ± 1.2 %, duration of diabetes 19.7 ± 10.4 years, mean eGFR 68.3 ± 24.1 mL/min/1.73 m2, median UACR 151 (IQR 309) mg/g Cr, RAS inhibitors usage 80.1%). The SGLT2i prescription rate was 58.9% in 2023. Coronary artery disease, age ≥65 years, eGFR
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes, Thyroid, and Endocrine Center, Vimut-Theptarin Hospital, Bangkok, Thailand.
Zitieren
APA
Chongvoranond, P., Thewjitcharoen, Y., Chatchomchaun, W., Wanothayaroj, E., Butadej, S., Nakasatien, S., Krittiyawong, S., & Himathongkam, T. (2025). Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:. Journal of the ASEAN Federation of Endocrine Societies, 40(2), 69-77. https://doi.org/10.15605/jafes.040.02.22
Vancouver
Chongvoranond P, Thewjitcharoen Y, Chatchomchaun W, Wanothayaroj E, Butadej S, Nakasatien S, et al. Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:. Journal of the ASEAN Federation of Endocrine Societies. 2025;40(2):69-77. doi:10.15605/jafes.040.02.22
BibTeX
@article{Chongvoranond2025,
author = {Chongvoranond, Peachaphol and Thewjitcharoen, Yotsapon and Chatchomchaun, Waralee and Wanothayaroj, Ekgaluck and Butadej, Siriwan and Nakasatien, Soontaree and Krittiyawong, Sirinate and Himathongkam, Thep},
title = {Sodium-Glucose Cotransporter-2 inhibitor (SGLT2i) Prescription Rates Amongst Diabetologists for Type 2 Diabetes Patients with Albuminuric Diabetic Kidney Disease:},
journal = {Journal of the ASEAN Federation of Endocrine Societies},
year = {2025},
volume = {40},
number = {2},
pages = {69--77},
doi = {10.15605/jafes.040.02.22}
}
EUVIMED